Medical Cannabis in the UK: Understanding Eligibility
Cannabis based medicines have been legal in the UK since November 2018 when prescribed by a specialist clinician. Despite this change in law, many patients remain unsure about when these medicines may be considered and how prescribing decisions are made.
This article explains the current regulatory framework and how clinicians assess whether cannabis based treatment may be appropriate.
Why Access Remains Limited
Cannabis based medicines for human use are generally considered unlicensed medicines in the UK. This means they have not followed the same licensing pathway as most commonly prescribed medicines.
Because of this, prescribing decisions are made cautiously and usually only after other treatment options have been explored.
Within the NHS, prescribing is currently very limited and typically restricted to certain specialist situations such as:
Severe treatment resistant epilepsy
Chemotherapy related nausea and vomiting
Spasticity associated with multiple sclerosis
Outside of these situations, prescribing decisions may occur through specialist clinics where clinicians can assess individual cases.
How Prescribing Decisions Are Made
Eligibility for cannabis based treatment is not determined by a single diagnosis alone.
Instead, clinicians consider a number of factors including:
• The severity and duration of symptoms
• Previous treatments that have been tried
• Potential risks or contraindications
• Whether alternative treatments remain available
In many cases, patients being assessed have previously tried conventional therapies without sufficient benefit or have experienced problematic side effects.
Conditions That May Be Considered
In clinical practice, specialist clinicians may sometimes consider cannabis based medicines when managing certain long term or complex conditions. These can include situations involving chronic pain, neurological disorders, or symptoms that have not responded to standard treatments.
However, suitability must always be assessed on an individual basis. Not all patients with these conditions will be appropriate candidates for treatment.
Clinical Safety Considerations
Cannabis based medicines may not be suitable for everyone. For example, clinicians may advise against treatment where certain psychiatric conditions are present or where other medical risks exist.
A full review of medical history and current medications is therefore an important part of the assessment process.
Clinical Review and Oversight
Where cannabis based treatment is considered, the prescribing process involves consultation with a specialist clinician. Follow up reviews are usually recommended to monitor response to treatment and assess ongoing suitability.
Specialist clinics such as Keltoi Clinic provide consultations where clinicians review patient history, discuss treatment options, and determine whether prescribing may be appropriate.
Conclusion
Cannabis based medicines are one of several treatment options that may be considered in specific clinical circumstances. Because these medicines remain tightly regulated, prescribing decisions require careful clinical assessment and ongoing monitoring.
Patients considering this type of treatment should seek advice from a qualified healthcare professional to understand the potential benefits and risks in their individual situation.
Information provided for general guidance only. Individual suitability is assessed by a clinician.